ASH 2019 | Mutant p53 re-activator APR-246 in MDS/AML
APR-246 is a novel, first-in-class small molecule that selectively induces apoptosis in TP53-mutated cancer cells via thermodynamic stabilization of the p53 protein and shifting of the equilibrium toward the wild-type conformation. David Sallman, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses the phase 2 (NCT03072043) results of APR-246 and azacitidine in patients with TP53 mutant myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
Get great new content delivered to your inboxSign up